2023
DOI: 10.1016/j.drup.2023.100962
|View full text |Cite
|
Sign up to set email alerts
|

Current therapy and drug resistance in metastatic castration-resistant prostate cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
45
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 95 publications
(45 citation statements)
references
References 119 publications
0
45
0
Order By: Relevance
“…Current metastatic castration-resistant prostate cancer (mCRPC) treatments include chemotherapy, endocrine therapy, and bonetargeting therapy [7] . After conducting an extensive review of the current literature, we have not come across any herbal medicine treatments for mCRPC.…”
Section: Current Treatmentsmentioning
confidence: 99%
See 4 more Smart Citations
“…Current metastatic castration-resistant prostate cancer (mCRPC) treatments include chemotherapy, endocrine therapy, and bonetargeting therapy [7] . After conducting an extensive review of the current literature, we have not come across any herbal medicine treatments for mCRPC.…”
Section: Current Treatmentsmentioning
confidence: 99%
“…Studies on new treatments such as pemetrexed have shown limited therapeutic advantages and increased toxicity. Clinical trials investigating traditional platinum-based chemotherapeutic agents are also occurring, but their efficacy has yet to be established [7] .…”
Section: Chemotherapymentioning
confidence: 99%
See 3 more Smart Citations